Life-threatening diarrhea afflicts a considerable percentage of patients treated with irinotecan, an anticancer agent with effects elicited through its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). The primary detoxification pathway for SN-38 is glucuronidation. The purpose of this study was to evaluate the role that intestinal UDP-glucuronosyltransferases (UGTs) have from hepatic UGTs in modulating this diarrhea. To investigate this, Gunn rats devoid of UGT1A activity were injected with recombinant adenoviral vectors expressing UGT1A1, 1A6, and 1A7, resulting in reconstituted hepatic UGT expression comparable to a heterozygote. Hepatic microsome studies indicated that 4 to 7 days after adenoviral injection, transfected Gunn rats (j/jAV) had SN-38 glucuronide (SN-38G) formation rates three times higher than control heterozygote rats (jϩAV). The adenovirus did not impart any glucuronidating capacity to the intestine in j/jAV rats, whereas jϩAV rats possessed intestinal UGT function. After the administration of 20 mg/kg/day irinotecan i.p. to j/jAV rats 4 days after adenovirus injection, diarrhea ensued before the fourth irinotecan dose. jϩAV rats were spared the diarrhea, and the toxicity was mild compared with the j/jAV rats, as measured by diarrhea scores, weight loss, and histological assessments of the cecum and colon. The pharmacokinetics of irinotecan, SN-38, and SN-38G indicate that the systemic exposure of SN-38 and SN-38G was higher and lower, respectively, in j/jAV rats. Despite this, the biliary excretion of irinotecan and metabolites was similar. Because intestinal UGTs are the main discriminating factor between j/jAV and jϩAV rats, their presence seems to be critical for the gastrointestinal protection observed in jϩAV rats.The UDP-glucuronosyltransferases (UGTs) are a superfamily of metabolic enzymes that catalyze the transfer of UDP-glucuronic acid to endogenous and xenobiotic substrates. Glucuronidation is a detoxification mechanism from several standpoints. It decreases the apparent volume of distribution, increases the molecular weight, and increases substrate specificity for active transport by imparting a negative charge, which are all processes that facilitate substrate elimination from the body (Guillemette, 2003). Furthermore, in most cases, glucuronidation renders the substrate inactive with respect to its pharmacological or physiological target. A Wistar-derived rat model of UGT1A subfamily deficiency, the Gunn rat, has allowed tremendous insight into the importance of the UGT1A family in the metabolism and toxicity of substrates (Wells et al., 2004). The abolition of UGT1A glucuronidation in these rats stems from a frameshift mutation that yields a truncated, nonfunctional protein unable to bind UDP-glucuronic acid (Iyanagi et al., 1989).Although the primary organ of glucuronidation receiving most attention has been the liver, research on intestinal UGTs has shown their importance. Large differences in protein levels of the UGT1A family are not observed between these ...